Since the discovery of the participation of various ion channels in the regulation of cell proliferation and programmed cell death two decades ago, the field exploring ion channel function in relation to cancer has undergone rapid development. Although the mechanisms accounting for the impact of ion channel modulators on cancer growth have not been fully clarified in all cases, numerous in vivo experiments targeting diverse ion channels in various cancer models illustrate the great potentiality of this approach and promote ion channels to the class of oncological targets. In the present review we give an updated overview of the field and critically discuss the promising results obtained in pre-clinical models using specific pharmacological modulators of calcium, sodium, potassium and anion-permeable ion channels, whose expression is often altered in tumor cells and tissues. The most, especially critical issues are specificity of action and side-effects. Interestingly, some of the most potent drugs are natural products, and several of the active compounds are already used in the clinic for other purposes. In these latter cases involving drug repositioning we may expect a faster progression from preclinical to clinical studies. This article is part of a Special Issue entitled: Calcium and Cell Fate edited by Jacques Haiech, Claus Heizmann and Joachim Krebs.
Introduction
Plasma membrane ion channels are trans-membrane proteins that selectively facilitate the permeation of specific ions between intracellular and extracellular environments. By controlling ion fluxes at multiple sites within the cells and on multiple time scales, ion channels shape rapid cell signals in excitatory tissues but are involved also in slower processes, such as proliferation (e.g. [1] [2] [3] ), volume regulation (e.g. [4, 5] ), apoptosis (e.g. [2, [6] [7] [8] [9] ), migration (e.g. [10, 11] ) and cell adhesion (e.g. [12] ) in non-excitable cells. Since the first reports linking ion channels to these processes (e.g. [13] [14] [15] [16] [17] [18] ) the field has undergone an exponential development and by now the scientific community accepted the idea that regulation of ion channel function during e.g. proliferation or apoptosis is not merely a "side-effect". Rather, channels play crucial modulating roles and are able to determine the fate of the cells. Indeed, a role of ion channels in cancer development has been hypothesized already two decades ago. Increasing evidence indicates that a variety of channel types not only in the plasma membrane but also in intracellular organelles are involved in neoplastic progression and importantly contribute to the acquisition of the main characteristics of the cancer cells [19] , including metabolic re-programming [20, 21] , limitless proliferative potential [22, 23] , apoptosis-resistance [8, 24] , stimulation of neo-angiogenesis [25] as well as cell migration and invasiveness [12, 26] . Thus, the channels impacting cancer development and progression have been defined as "oncogenic channels". Tumor progression leads to the acquisition of a specific molecular profile, giving rise to different malignant clones which display altered genotypic and phenotypic characteristics. In this respect, identification of the "channelome", i.e. of the type and expression level of a certain set of ion channels, of different cancer types is especially important, since ion channels not only contribute to malignant progression, but also offer a possibility of therapeutic intervention. Determination of the "channelome" in pathologic tissues might help to set up strategies to specifically target cancer cells but not healthy tissues, in contrast to the most widely used chemotherapeutics which affect the most rapidly proliferating cells.
Indeed, much convincing in vitro work by many different laboratories has established that modulation of ion channels in cancer cells by either altering their expression or using inhibitors/activators may impair the growth and/or migration of these cells. On the other hand efficacy against cultured cancer cells is not necessarily maintained when moving to more complex in vivo systems, since, for example pharmacokinetic properties of the anti-tumoral agents or effective drug delivery to tumor tissues in the case of solid tumors might not be satisfactory. Furthermore, the importance of the tumor microenvironment, with its immunomodulatory, pro-inflammatory and anti-apoptotic roles, is Biochimica et Biophysica Acta xxx (2015) xxx-xxx coming into full focus (e.g. [27] [28] [29] ). The tumor niche cannot be fully reconstituted in vitro. Nonetheless, recent in vivo studies demonstrate the efficacy of ion channel targeting, consecrating this class of proteins as promising pharmacological targets in oncology. Fig. 1 . summarizes the various types of ion channels present in different tumor tissues, whose targeting yielded significant inhibition of tumor growth in vivo in animal models.
The primary scope of the present review is to give and updated overview of recent advances regarding pharmacological targeting; therefore, the specific mechanisms responsible for the tumor-reducing effects will be only briefly mentioned. For most of the channel proteins we discuss, evidence has been gained of their altered expression in tumor tissues with respect to healthy tissues, but for sake of simplicity we do not refer to these data. In general, while convincing cases of reduced tumor growth by application of channel inhibitors exist in the literature, in a few instances the mechanism is likely to be unrelated to their channel-inhibitory function, and/or, in several cases, the demonstration that the drugs inhibits proliferation via its action on ion channels is missing.
Calcium-permeable channels

Intracellular Ca
2+ homeostasis impacts cell cycle checkpoints, apoptosis, autophagy, migration and release of soluble modulators such as neurotransmitters, hormones and growth factors in both normal and neoplastic cells [30] [31] [32] [33] . Major Ca 2+ influx pathways include voltage-gated Ca 2+ channels (VCC; L-type: Ca V 1. a role in restoring resting Ca 2+ i by actively exporting calcium to the extracellular millieau (for recent reviews see e.g. [30, 36] ). In addition, acidic endogenous compartments such as lysosomes and lysosomerelated organelles harbor functionally active Ca 2+ -permeable TRP channels (the main type is TRPML, mucolipin) and TPC two pore channels as well as P2X receptors [37, 38] .
Voltage-gated calcium channels
Among the compounds targeting the Ca 2+ cyt -regulating systems mentioned above, some ion channel antagonists have been shown to impact on tumor size in various models. The expression of VCCs is a characteristic of excitable cells, but some members (especially of the Ca V 3 subfamily), are expressed in a number of cancer cell lines where they modulate proliferation [39] . One of the first in vivo studies has been performed in 1992 using structurally unrelated L-type voltagegated calcium channel antagonists (CCA) amlodipine, diltiazem, and verapamil, all of which inhibit proliferation of HT-39 human breast cancer cells with IC 50 values ranging from 1.5 μM (for the dihydropyridine amlodipine) to 10 μM (for the phenylalkylamine verapamil). Clinical studies in humans showed that verapamil acts as a chemo-sensitizer, overcoming multi-drug resistance (MDR) pump-mediated resistance to anthracycline and increasing survival of patients with metastatic breast carcinoma [40] . Its mechanism of action may thus be related more to its interaction with other channels, such as those selective for sodium (e.g. [41] ) and potassium (e.g. [42, 43] , and with P-glycoprotein/MDR1 (e.g. [44] ) than to Ca 2+ channel inhibition. CCAs have been proposed to be tested in clinical trials in adjuvant therapy for recurrent or unresectable meningiomas [45, 46] . In vivo in an animal model of breast cancer, oral administration of amlodipine (0.35 mg/day), diltiazem (3.5 mg/day) or verapamil (3.5 mg/day) for 10 days inhibited HT-39 breast tumor growth by 83.5 ± 20.1% (mean ± SE), 46.5 ± 6.6% and 68.2 ± 9.7%, respectively [47] . However, the mechanism responsible for the in vitro and in vivo effects could not be clarified, since HT39 cells were found not to express VCCs. Interestingly, the dihydropyridine (DHP) amlodipine proved to be the most efficient drug in vivo but not all compounds in this class display anti-proliferative effects in vitro. For example, while amlodipine, nicardipine and nimodipine, inhibited the growth and DNA synthesis of human epidermoid carcinoma A431 cells with IC 50 values of 20-30 μM, the structurally related nifedipine did not exert such an effect [48] . In addition, the L-type voltage-gated calcium channel activator (F)-Bay K8644) did not prevent the anti-proliferative effect of the above DHP inhibitors, again pointing to a VCC-independent mechanism of action and in agreement with the finding that these cells do not express L-type VCC [49] . Daily intraperitoneal administration of amlodipine (10 mg/kg) for 20 days into mice bearing A431 xenografts, retarded tumor growth and prolonged the survival of mice: at day 23 post tumor inoculation, tumor size was reduced by more than 55%. Furthermore, clinical trials for the use of amlodipine in the treatment of hypertension suggest that longterm treatment with these agents (at concentrations comparable to those used in the above studies) does not cause significant toxicities. But what is the mechanism of action of amlodipine? In A431 cells amlodipine has been shown to attenuate capacitive Ca 2+ entry via intracellular store-depletion activated calcium channels, I CRAC [48] . Recently, the same group provided evidence that these cells express canonical transient receptor potential 1 (TRPC1) and TRPC5 which might mediate calcium influx and found that amlodipine arrested cell cycle progression at the G1 phase by inducing a cyclin-dependent kinase inhibitor [50] . Finally, amlodipine was found to inhibit tyrosine phosphorylation of EGFR both in vitro and in vivo, possibly by modulating cholesterol-rich, caveolin-1-containing membrane microdomains and thus impacting on EGFR-related mitogenic signaling [51] . At the same time, the effect of this drug on rafts might also have an impact on the SOC channels (especially TRPC) mediating I CRAC (e.g. [52] , which in turn seem to be essential components of a Ca
2+
-dependent signal amplification required for EGF-dependent cell proliferation [53] . To our knowledge a systematic study unequivocally linking only the CCA drugs that inhibit cell proliferation to the above events has not been performed up to now. This would be important in order to generalize the observed effects and to confirm amlodipine as promising, lead compound for the development of derivatives as anti-tumor agents acting on mitogenic signaling.
Although in the above examples the CCA drugs presumably reduce tumor growth independently of their direct inhibitory effect on L-type calcium channels, targeting of the T-type VCCs by the selective inhibitor KYS05047 (a 3,4-dihydroquinazoline derivative; IC 50 for T-type channels:~0.2 μM) does so thanks to its ability to decrease intracellular calcium concentration [54, 55] . Growth of human lung adenocarcinoma A549 cells was time and dose-dependently inhibited by KYS05047, 6-8 μM being the optimal, non-cytotoxic concentration. The authors provided in vitro evidence that these drug concentrations induced a reduction of the cyclin-dependent protein kinases cdk2 and cdk4, a reduction of the phosphorylation of the tumor suppressor protein RB (retinoblastoma) and of Akt and mTOR and as a consequence, an arrest of the cell cycle in G1 phase. The authors proposed that these events took place as a results of the reduction of cytosolic Ca 2+ and of the activation of Ca 2+ /calmodulin-dependent protein kinases (CaM-K), whose downstream effectors (e.g. Rb and the Akt pathway) play a role in the G1 to S transition [56] . Unfortunately, the specificity of the effect has not been investigated, e.g. by downregulation of the channel protein using siRNA, but oral administration of 10 mg/kg KYS05047 for 21 days in a BALB/cnu/nu mouse A549 xenograft model reduced tumor volume by approximately 50%. Whether this drug caused side effects and whether it prolonged animal survival has not been investigated. Another T-type calcium channel inhibitor, mibefradil, was also shown to impact in vivo on tumor growth in a glioblastoma model (C6 glioma). This compound, also known as Ro 40-5967, was approved by FDA for treating hypertension but it was then withdrawn by the producer (Roche) due to dangerous drug-drug interactions. It inhibits T-type channels with an IC 50 of~3 μM vs.~18 μM for L-type channels [57] . The study involved administration of 30 mg/kg (intraperitoneally 3 times a day for 1 week) in combination with ionizing radiation [58] . The animals treated with mibefradil starting on postoperative day (POD) 15 followed by radiosurgery on POD 22, survived twice as much as the animals treated only with radiosurgery. In addition, mibefradil (45 mg/kg PO four times daily) in co-administration with temozolomide (an alkylating agent; 10 mg/kg/day IP) increased maximal survival from 20 days to 120 days in a D-54 MG xenograft model for glioblastoma multiformae [59] . A clinical trial is therefore underway to evaluate the effect of mibefradil in patients with progressive or recurrent glioblastoma following radiation therapy and the currently used chemotherapeutic temozolomide. As mentioned, CCAs have been proposed for testing in clinical trials as an adjuvant therapy for meningiomas [45, 46] . Mibefradil, similarly to other VCC inhibitors, blocks cell cycle progression beyond the G1/S interphase, but also induces apoptosis by causing PM depolarization and by decreasing integrin expression and thus cell adhesion [60] . Interestingly, mibefradil and its derivative NNC 55-0396 were recently identified in a large-scale screening as down-regulators of mitochondrion-mediated hypoxia-inducible factor (HIF)-1α protein stability and angiogenesis inhibitors [61] . Ca 2+ signaling has been shown to stimulate translation of HIF-1α during hypoxia [62] . The activity of this transcription factor is related to tumor cell survival, proliferation, and angiogenesis, but how exactly these drugs affect HIF-1α protein stability is still an open question. The finding that knockdown of T-type Ca 2+ channel also suppressed hypoxia-induced HIF-1α
protein stability specifically links this type of VCC to the effect of mibefradil and NNC 55-0396. The question arises whether any agent affecting intracellular Ca 2+ homeostasis might affect HIF-1α stability. Calcium signaling has been shown to stimulate translation of HIF-alpha during hypoxia (e.g. [62] ) and for example artemisinin and parthenolide, two SERCA inhibitors, induce phosphorylation of HIF-1α [63] . The L-type calcium channel blocker cilnidipine selectively suppressed HIF-1α activity in vascular cells [64] and expression of (HIF)-1/2α was significantly reduced in a neuroblastoma cell line expressing a dominant negative form of TRPM2 channel, the presence of which reduces calcium influx into these tumor cells in response to oxidative stress [65] . Using a mouse tumor xenograft model into which U87-MG human glioblastoma cells were injected, Kim and colleagues demonstrated that intraperitoneal administration of 10 or 20 mg/kg NNC 55-0396 was sufficient to reduce tumor volume by more than 60%, as well as angiogenesis, without inducing liver toxicity [61] . Finally, the case of simvastatin can be mentioned: this statin has been shown to reduce tumor growth in colitis-associated colon cancer (CAC) model in vivo by inducing apoptosis [66] , and at the same time it has been recently suggested to inhibit calcium influx via L-type VCC [67] . However, simvastatin is likely to exert pleiotropic effect and the relevance of its action on L-type VCC in vivo has not been addressed up to now. In summary, VCCs are potential oncological targets of demonstrated importance. The advantage of using drugs targeting VCCs is that most of these drugs have been approved by FDA for curing hypertension. The major shortcoming of this field is however that for most of the drugs the specificity of the effect via VCCs and the exact mechanism of action have not been fully demonstrated. As described above, some of the most promising drugs, like mibefradil, have multiple effects which impact tumor growth, therefore making these drugs good candidates for co-adjuvant therapies [68] .
Transient receptor potential channels
Beside VCCs, TRP proteins are emerging as promising oncological targets [36, 69] . TRP channels can be divided into subfamilies, namely TRPV (TRP vanilloid), TRPA (TRP ankyrin), TRPM (TRP melastatin), TRPC (TRP canonical) and TRPP (TRP polycystin). Mammalian TRP proteins form homo-or hetero tetrameric non-selective Ca 2+ -permeable cation channels which can be stimulated by a variety of different factors, including change in temperature, mechanical stress, osmotic pressure, change in pO 2 and in pH, ROS, growth factors and cytokines. Therefore, they are expected to play a crucial role in the tumor-microenvironment cross-talk. TRPC channels are activated through pathways coupled to phospholipase C (PLC), and can support receptor-operated Ca 2+ entry;
TRPC1 and TRPC4 can also contribute to SOCE via relatively nonselective cation currents. Several investigations found evidence for a role of TRPC channels in the regulation of hallmark cancer processes by using genetic modulation of their expression (e.g. [53] ). Thus, knockdown of TRPC1 decreased tumor volume by 40% in a xenograft model using human grade IV glioma cell line D54MG [70] . However, a pharmacological agent that specifically targets a TRPC subtype became only recently available (e.g. [71, 72] . A recent piece of work demonstrated that the sesquiterpene (−)-englerin A is a selective and potent activator of TRPC4 and 5 [73] and inhibits tumor cell growth by activating these ion channels, thereby inducing massive calcium influx and consequent cell death. Unfortunately, the concentrations at which englerin A activates a calcium influx (around 250 nM) are in the range in which englerin A was lethal within a few hours in rodents (132-544 nM) [74] . Interestingly, another natural compound, 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (20-GPPD), a metabolite of ginseng saponin induced TRPC-mediated calcium influx into CT-26 colon cancer cells and AMPK kinase-dependent apoptosis in vitro. In vivo, daily injection of 20-GPPD (1 mg/kg) for 4 weeks reduced tumor weight by 75% [75] . However, which TRPC channel is targeted by this compound is unclear, as is the mechanism accounting for the selective effect of 20-GPPD on cancer cells.
Among TRPV channels, the highly calcium-selective channel TRPV6 (which allows however the passage of heavy metals zinc, manganese and cadmium as well [76] ) has been found to be expressed in a variety of cancers including prostate and breast. Its expression correlates with cancer progression, suggesting that it drives cancer cell growth. TRPV6 indeed acts as oncogenic ion channels [77, 78] . A few years ago, a synthesized derivative of TH-1177 was proven to be a specific inhibitor, capable of distinguishing between TRPV5 and TRPV6 and to block the proliferation of LNCaP human prostate cancer cells with and IC 50 of 0.44 μM [79] . The same group has also achieved the synthesis of TRPVinhibiting drugs starting from 2-Aminoethyl-diphenylborinate (2-APB), a known modulator of the IP3 receptor, of SERCA, of Orai and of TRP channels. One of the analogs is more efficient than 2-APB in blocking TRP channels, but it also blocks SERCA [80] . To our knowledge this study has not been followed up in vivo so far. Interestingly, two short peptides that derive from Soricidin, a novel paralytic peptide isolated from Blarina brevicauda were shown to bind TRPV6 in ovarian cancer cells with high affinity and can be exploited via conjugation with fluorescent dye for in vivo imaging of human ovarian tumors in a xenograft mouse model [81] . Whether these peptides show an antitumor activity in vivo is still to be tested. The prototypical vanilloid agonist capsaicin, the well-known ingredient of chili peppers, which activates both TRPV6 and TRPV1, was shown to induce apoptosis by its action on TRPV6 (as proven using siRNA) and downstream activation of calpains at 50 μM concentration in human small cell lung cancer cells (SCLC) in vitro while leaving unaffected normal human bronchial epithelial cells [82] . Importantly, in vivo dietary administration of capsaicin (50 mg capsaicin/kg food) almost completely blunted growth of DMS 53 human SCLC tumors xenografted in nude mice [82] . In T24 bladder cancer cells T24 200 μM Capsaicin caused significant TRPV1-dependent apoptosis by inducing ROS release and mitochondrial depolarization. In vivo, subcutaneous injection of 5 mg/kg capsaicin every 3 days for 4 weeks reduced the growth of T24 bladder cancer xenografts only slightly, by 15% [83] . Mitochondrial depolarization but not increased ROS release has been observed also in BON and QGP-1 NET pancreatic neuroendocrine tumor cells in vitro upon capsaicin treatment at high concentration [84] . In yet another study, the vanilloid receptor TRPV antagonist capsazepine (CPZ) proved to be more cytotoxic than capsaicin for some cell lines. ROS release by CPZ was related to apoptosis in oral squamous cell carcinoma cells (OSCC), but was found to be independent of TRPV1. Importantly, in three different OSCC xenograft models, intra-tumoral injection of max. 40 μg CPZ every other day for 18 days completely blunted tumor growth in two out of the three models used [85] . In addition, the authors also provided evidence that liver and kidney function had been preserved. Survival of immortalized normal oral keratinocytes was not affected. Mitochondrial Δψ loss and increased ROS release was associated with apoptosis in PC-3 prostate cancer cell line as well and subcutaneous injection of either capsaicin or capsazepine (5 mg/kg body weight) in nude mice significantly suppressed PC-3 tumor growth by inducing apoptosis of tumor cells [86] . Thus, capsaicinoids seem to have a very promising in vivo effect in various tumor models and most probably affect cell apoptosis via TRPV1 and/or TRPV6, in particular by inducing oxidative stress by still unknown mechanism. Most cancer cells display an increased metabolic activity and are therefore under oxidative stress. Increase in ROS by an external agent may disrupt this delicate balance between ROS levels and the anti-oxidant capabilities of the cancer cells thereby triggering ROS-induced apoptosis, without inducing the same impact on the healthy tissues [87] .
Finally, it is of note that some cannabinoid compounds, in particular cannabidiol (CBD), stimulate TRPV1 while the non-psychotropic cannabigerol (CBG) is an antagonist of TRPM8 [88] . CBD displayed and anti-invasive action which depended on the effect of CBD cannabinoid receptor and TRPV1. In vivo, in a nude mice injected with human lung carcinoma A549 cells, intraperitoneal application of 5 mg/kg body weight CBD every 3 days for 28 days almost completely abolished the appearance of metastatic nodules [89, 90] . CBD was employed also in a study with prostate carcinoma LNCaP cells, where the pro-apoptotic effect of CBD was interpreted as partly due to TRPM8 antagonism and was accompanied by ROS release and p53 activation. In this case, in vivo, application of 100 mg/kg CBD i.p. daily plus 5 mg/kg docetaxel, i.v. once a week reduced tumor volume by approximately 60% when compared to untreated animals [91] . Furthermore, CBG and other TRPM8 antagonists hampered colon cancer progression in xenograft tumors as well as chemically induced colon carcinogenesis [92] .
Altogether, these results point to the relevance of TRP channel modulators for cancer treatment, especially in light of the fact that both capsaicinoids and cannabinoids are natural substances. However, given the pleiotropic effects of these drugs, a definitive proof demonstrating the requirement for channel activation or inhibition in relation to the anti-tumoral effects should ideally be provided for all cases.
Orai and STIM1
As mentioned above, SOCE, mediated by Orai and STIM1 proteins has been linked to the proliferative potential of various cell types [93] [94] [95] and to the resistance to apoptosis of cancer cells [96] . Ca 2+ signaling mediated by TRP channels and by Orai/STIM1 directly or indirectly influences cancer and stroma cell migration [11] . In patients with esophageal squamous cell carcinoma (ESCC), high expression of Orai1 was associated with poor overall as well as recurrence-free survival [97] . Orai1 sustained cell proliferation, migration and invasion of KYSE-150 cells, an epithelial line derived from human ESCC tumor. In a mouse model, treatment (10 μg/g body weight, three times weekly i.p.) for four weeks with SKF96365, an inhibitor of SOCE (e.g. [98] ), decreased tumor volume by approximately 50%. Although SKF96365, a phenylethylimidazole, is not very specific and inhibits TRPC and VCCs as well [71] , an almost complete tumor-reducing effect was observed in vivo by silencing Orai1, indicating that indeed this SOCE component is fundamental for the development of ESCC [97] . In accordance with the fundamental role of SOCE in the above example, STIM1 expression was also found to be elevated in cervical cancer patient tissues and correlated with tumor size. Overexpression or knockdown of STIM1 in cervical cancer SiHa cells exacerbated or blunted tumor growth in SCID mice, respectively. I.p. injection of these mice bearing tumor xenograft of SiHa cells with SKF96365 (2.5 mg/kg), or 2-APB (2-aminoethoxydiphenyl borate; 50 μg/kg) from the sixth day postinoculation for 9 days completely abolished tumor growth [99] . 2-APB not only is used as a modifier of SOCE but also acts on IP3Rs and TRPV and TRPC channels [100, 101] . Chen and coworkers [99] however proved by genetic means that STIM1 overexpression enhanced invasive migration and VEGF secretion in vitro and, coherently, angiogenesis and local invasion. Thus, even though the pharmacological agents used are not specific, it seems clear that they targeted the STIM1/Orai1 complex. Hopefully, thanks to the resolved crystal structure of Orai1 [102] , structure-based drug design strategy will provide more specific inhibitors [103] . However, since STIM and ORAi proteins are ubiquitously expressed, toxicity to normal cells should also be considered when SOCE inhibitors are applied systemically. In the above mentioned papers the question of toxicity has not been addressed in depth.
P2X receptors
The P2 family of receptors is comprised of P2Y metabotropic and P2X ionotropic receptors, the latter behaving as nonselective cation channels permeable to calcium, sodium, and potassium ions. ATP-mediated intercellular signaling is implicated in a wide range of physiological processes, including neurotransmission, neuromodulation, chemoattraction or chemotaxis, and pain. One of the first investigations linking P2X receptors to cancer reported that statins -shown to reduce the risk of pancreatic cancer by 80% in humans according to a case control study with half a million veterans [104] and to reduce pancreatic tumor growth in mouse models (see e.g. [105] ) -probably act via P2X7 receptors [106] . In this in vitro work, the authors showed, using genetic tools that the decrease in pAkt level, the inhibition of cell proliferation and apoptosis induction by statins, in particular atorvastatin, was dependent on P2X7 expression. Following this lead, in vivo experiments in different tumor models have been conducted to support a role of P2X7 receptors in cancer progression. Tumor tissues contain much higher concentrations of extracellular ATP (hundreds μM range) than healthy tissues, [107, 108] . ATP activates P2X receptors, among which P2X7 has been found to be highly overexpressed in several cancer types. In a zebrafish model using the highly metastatic cancer line MDA-MB-435, 10 μM A-438,079, a P2X7 antagonist halved the % of zebrafish with metastasis [109] . The same group later reported that emodin (1,3,8-trihydroxy-6-methylanthraquinone), an anthraquinone derivative of Rheum officinale with known anticancer properties, specifically inhibited P2X7-mediated currents with an IC 50 of 3 μM [110] . In the same zebrafish model, in vivo invasiveness of the P2X7R-positive MDA-MB-435 cells was reduced by 50% using 10 μM emodin. Two other studies independently demonstrated that oxidized ATP (0.5 mg/mouse 3 times i.p.), a selective antagonist of P2X7, significantly reduced tumor volume in a B16 melanoma-bearing mice model [111] as well as in a colon cancer CT26 model (reduction by 90% with 3 intratumoral injections of oxATP (600 mmol/L) [112] . The same authors also showed that intratumoral injection of 300 nmol/L of the selective P2X7 inhibitor AZ10606120 caused a strong inhibition of melanoma B16 tumor growth as well. Interestingly, ATP was used also in a previous study against A375 melanoma cells and similarly to oxATP, an N50% reduction of tumor volume could be observed [113] .
Potassium channels
As illustrated by the above examples, pharmacological targeting of different calcium-permeable channels may have a dramatic impact on tumor growth in vivo. Given the central role of calcium signaling in contributing basically to all aspects of the cancer hallmarks, these successful cases are not surprising. Beside calcium channels however, potassium sodium and chloride channels can also be successfully targeted and in some cases this strategy has already led to clinical trials in humans. Indeed, these channels are equally important for tumor development and progression as we know by now from numerous in vitro and some in vivo experiments. The first potassium channel with suggested oncogenic potential was a member of the voltage-gated Kv family, Kv11.1 (hERG) [114] , shown to control the membrane restingpotential of neuroblastoma cells which was related to their proliferative abilities as described by Arcangeli and co-workers [115] . The first ion channel with proven oncogenic potential was Kv10.1 (EAG) [14] , which can be detected in approximately 70% of human tumor biopsies of diverse origin [22] . In this seminal work, Stuhmer and colleagues proved that expression of both EAG and of the voltage-dependent Kv1.4 in non-tumoral Chinese hamster ovary cells conferred a transformed phenotype and in vivo both channel-transfected lines favored tumor progression when injected into the flank of immune-depressed mice. The size of the tumor obtained using the EAG-expressing line was twice as much as that observed with Kv1.4, indicating the expression of EAG (expressed only in the brain in healthy subjects but in different cancer cell types in cancer patients) gives rise to a more aggressive behavior. Soon after the discovery that this specific channel is so important for proliferation and tumor progression, several independent studies suggested that this is a general feature of potassium channels. Indeed, K + channels regulate cell cycle by affecting trans-membrane potential across the PM [22] since they set the resting membrane potential in both excitable and non-excitable cells: in general, the membrane potential varies during cell cycle (with hyperpolarized value and high permeability for K + at the G1 to S transition) [116] and cell types with a very hyperpolarized resting potential do not readily undergo mitotic division. Membrane potential in turn impacts on calcium entry and calcium signaling (for review see e.g. [23] ). Furthermore, some K + channels proved to play an important role for angiogenesis: for example Eag1 was shown to increase HIF1α activity and angiogenesis [117] . Changes in channel expression, due to genomic, transcriptional, post-translational or epigenetic alterations, often occur in cancer cells (for recent review see e.g. [118] ) and are correlated with increased proliferative potential and/or altered apoptosis resistance (for review see e.g. [6] . A variety of K + channels, such as voltage-gated K + channels (Kv), calcium-activated K + channels (K Ca ) and ATP-sensitive K + channels (K ATP ) show altered expression in tumor tissues (e.g. [118, 119] ). Among the potassium channels, much attention has been dedicated to the pharmacological targeting of Kv10.1 (EAG), Kv11.1 (hERG) and the calcium-dependent potassium channel K Ca 3.1 for cancer treatment. A monoclonal antibody specifically produced against Kv10.1 inhibited the function of the channel, the colony forming ability of several different types of cancer lines and the in vivo tumor growth of the highly metastatic MDA-MB-435S cancer cells [120] . Furthermore, the open channel blocker astemizole (50 mg/kg, administered orally, daily), which does not cross the blood brain barrier and therefore does not affect neuronal EAG activity and is already used in the clinic, inhibited MDA-MB435S xenograft tumor growth by approximately 30% and growth of EAG-expressing CHO by 50% [117] . In vivo application of a combined therapy, using oral astemizole (50 mg/kg/day) and intraperitoneal injections of the active vitamin D calcitriol (0.03 μg/g body weight twice a week for 3 weeks), in mice xenografted with the human breast cancer cell line T-47D or with a primary breast cancerderived cell culture (MBCDF), resulted in 85% inhibition of tumor volume. This treatment was more efficient than application of either drug alone [121] .
Similarly to Kv10.1, Kv11.1 (hERG) is frequently overexpressed in cancer cells (e.g. [122] ) and it is implicated in tumor progression and migration via regulation of HIF1α stability and of integrin function/ adhesion-dependent signaling [123] . In vivo experiments using hERG1 blockers demonstrate the importance of hERG function in various systems: in a recent study, colorectal cancer cells (HCT116) were injected into nude mice that were then treated with specific Kv11.1 inhibitors WAY123,398 and E4031 (both substances at 20 mg/kg, i.p. for two weeks daily). An approximately 50% reduction of the tumor volume has been detected, but most importantly these drugs were very effective also using the same line that lacked p53 and inhibited both angiogenesis and metastasis [124] . Similar results were obtained in azoxymethaneinduced colorectal carcinoma [125] and in a gastric cancer model [126] : in the former case i.p. injections of E-4031 for 3 months caused an 80% reduction in the number of colonic polyps, while in the latter study combined application of 20 mg/kg E-4301 and of the anti-VEGF-A antibody bevacizumab almost completely abolished tumor growth. In addition, block of hERG in immune-deficient mice decreased the bone marrow engraftment and peripheral blood invasion of myeloid/ lymphoblastic leukemia cells and could overcome mesenchymal stroma cell (MSC)-induced chemoresistance in vivo in leukemia mouse models (E4031 administered daily at 20 mg/kg for max. 4 weeks) [127] . However, most of the drugs that modulate Kv11.1 function are associated with cardiotoxicity, either the long QT syndrome or fatal arrhythmias which can be triggered by class III antiarrhythmic drugs such as E4031 and Way 123,398. Given that tumor cells seem to preferentially express a different splice variant of Kv11.1, i.e. hERG1B (e.g. [128] ) with respect to the cardiac tissue, drugs acting exclusively on the tumor-associated variant might be of great therapeutic utility. In this respect, it is interesting to note, that ZC88, a novel 4-amino piperidine analog inhibited the tumor growth in nude mice engrafted with SH-SY5Y neuroblastoma cells by 60% at a dosage (50 mg/kg, i.p. application every 4 d for 16 days) that only slightly influenced the cardiac QT interval. A previous study identified ZC88 as blocker of the N-type calcium channel (IC 50 value of 0.45 μM), although the ZC88-mediated anti-proliferative effect was not correlated with its effect on the calcium channel activity [129] . Recently, another, very promising molecule which is specific for the hERG1B variant has been identified: CD-160,130, a novel pyrimidoindole compound block this isoform with an IC 50 value (1.8 μM) that is ten-fold less with respect to that obtained for hERG1A. This drug caused apoptosis in vitro and in vivo (10 mg/kg) reduced leukemia burden by 90% in a preclinical SCID leukemia model using HL60 cells. As expected, this compound did not induce any cardiotoxicity and enhanced long-term survival [130] .
Thus, numerous in vivo models illustrate very convincingly that both EAG and hERG are especially promising oncological targets. In vivo studies targeting other K + channels also point to an important role of K + channels in general to the tumor progression. As to other Kv channels, recent in vitro data pointed out that selective blockers of voltage-gated K + (Kv) channels or ATP-sensitive K + (KATP) channels significantly inhibited the proliferation of U87-MG human glioma cells, blocked the cell cycle at the G0/G1 phase and induced apoptosis. In the U87-MG xenograft model in nude mice, suspensions of the cells treated with 4-AP (5 mmol/l), TEA (20 mmol/l) or glibenclamide (200 μmol/l) were injected. The growth of the K + channel inhibitor-treated cells was reduced by 50%, but the specificity of the effect has not been demonstrated nor the specific Kv channel responsible was identified [131] .
In vivo evidence for the involvement of Kv1.3 in tumor growth has been obtained in an A549 human lung adenocarcinoma model: margatoxin (Mgtx), a selective blocker of Kv1.3 (IC 50 2 nM) or short hairpin RNA (shRNA) against Kv1.3, significantly blocked cell proliferation and intra-tumoral injection of 1 nM Mgtx for seven days reduced tumor volume in vivo by 75% [132] . Inhibition of Kv1.3 significantly increased expression level of p21
Waf1/Cip1 and decreased the expression level of Cdk4 and cyclin D3, altogether inhibiting G1 to S transition. The in vivo anti-proliferative effect of Mgtx was confirmed also in an independent work, in an orthotopic melanoma model using B16F10 cells [133] . Furthermore, this study revealed for the first time, that membrane-permeant Kv1.3 inhibitors such as Psora-4, PAP-1 and clofazimine, were able to induce apoptosis of different cancer cell lines, via their action on the mitochondrial counterpart (mtKv1.3) of the plasma membrane-located Kv1.3 [134] . Importantly, this effect was observed exclusively with the membrane-permeant inhibitors and genetic deficiency or siRNA-mediated downregulation of Kv1.3 abrogated the effects of these drugs, which also killed cells in the absence of Bax and Bak, in agreement with the following, experiment-based model: block of mtKv1.3 inhibits depolarizing influx into the mitochondrial matrix with consequent hyperpolarization. This alteration leads to significant ROS production by mitochondria which in turn opens the permeability transition pore (PTP), induce cytochrome c release independently of the pro-apoptotic Bax and Bak molecules and finally triggers apoptosis [21, 135] . Since hyperpolarization also provides an increased driving force for the mitochondrial calcium uptake system, the calcium uniplex (MCU) [136, 137] and a matrix calcium overload is known to trigger opening of the PTP, we checked whether knockdown of the channel forming MCU protein impacts signaling in the above system. MCU itself might become a good oncological target, similarly to other intracellular channels and to PTP [20, 21] , once specific activators will be identified. As Fig. 2 illustrates, the mtKv1.3 inhibitors exerted the apoptosis-inducing effect to the same extent, suggesting that an interplay between mtKv1.3 and MCU does not play a role in our experimental model. In vivo, intraperitoneal injection of clofazimine in an orthotopic melanoma B16F10 mouse model reduced tumor size by 90%, without causing visible side-effects as assessed by histology [133] . Expression of Kv1.3 in different cancer lines correlated with the sensitivity of the cells toward the above inhibitors [138] . In accordance, primary B cells obtained from patients suffering of chronic lymphocytic leukemia that expressed high level of Kv1.3 also in their mitochondria, readily underwent apoptosis upon treatment with the above Kv1.3 inhibitors while T cells from the same patients were resistant [139] . Coculturing with MSC did not reduce the ability of these drugs to kill the pathologic B cells [140] . Using primary B cells from patients or healthy subjects, it was possible to provide evidence that the selective cancer cell-killing action of mtKv1.3 inhibitors can be ascribed to a synergistic effect between altered redox state of cancer cells and the ability of these drugs to induce drastic ROS increase, thereby forcing the cell to cross the critical ROS threshold (see above). Because clofazimine is already used clinically to treat some autoimmune diseases and leprosy and shows an excellent safety profile [141] , targeting mtKv1.3 is a feasible cancer therapy for at least some cancer types. In general, targeting of mitochondrial channels represents and interesting strategy since alteration of mitochondrial bioenergetic efficiency and function which may be achieved by changing ion channel function [142] can have a dramatic consequence on cell fate (see e.g. [21, [143] [144] [145] . In addition to Kv potassium channels, calcium-dependent potassium channels and the two pore TASK-3 channel have been identified as oncological targets e.g. [146, 147] , but in vivo evidence by specific pharmacological targeting of TASK is still missing to our knowledge. As to K Ca 3.1, an important role for this channel in natural killer lymphocytes (NK), known to participate in the killing of cancerous cells. TRAM-34 and NS6180, two specific inhibitors of K Ca 3.1 increased proliferation of the NK cells as well as their ability to reduce in vivo tumor growth of the leukemic K562 cells [148] . Block of PM-located K Ca 2.3 (SK channel) has an impact on the migration of tumor cells: the edelfosine-like alkyllipid inhibitor named Ohmline ((1-O-hexadecyl-2-O-methyl-snglycero-3-lactose) was shown to block SK channel with and IC 50 of 300 nM [149] and was able to prevent bone metastasis of the highly metastatic MDA-MB-435 cells [150] . Intravenous application of 15 mg/kg Ohmline 3 times a week for 15 weeks reduced by 50% lung metastasis and completely blocked bone metastasis without impacting on the primary tumor volume. Interestingly, the authors provided evidence that Ohmline acted as a disrupting agent for lipid raft localization of the SK3-Orai1 complex, this way the SK3-Orai1 complex moved away from lipid rafts, and SK3-dependent Ca 2+ entry, migration, and bone metastases were impaired. In this respect it is interesting to note that several studies demonstrated that sphingolipids are involved in the regulation of SOCs [151] [152] [153] . These studies focused in particular on ceramide and sphingosine. Cellular ceramide is either de novo synthesized or released from sphingomyelin by the activity of neutral or acid sphingomyelinases. Ceramide is then converted by acid or neutral ceramidase to sphingosine, which can be phosphorylated to sphingosine 1-phosphate by the activity of sphingosine kinase 1 and 2 [154] . Ceramide molecules dramatically alter the biophysical properties of cell membranes, since they spontaneously associate with each other to form small, relatively rigid, gel-like ceramide-enriched membrane domains. These small domains spontaneously fuse to highly hydrophobic, tightly packed, and gel-like large ceramide-enriched membrane domains, also termed platforms, that serve the organization of membranes and proteins within membranes [155] [156] [157] . Ceramide molecules also exclude cholesterol from membrane domains further promoting the unique properties of ceramide-enriched membrane domains. Ceramide-enriched membrane platforms serve to bind, trap and reorganize receptors, ion channels and intracellular signaling molecules and, thus, facilitate signal transduction. Consistent with this notion are the results of studies showing that receptors such as CD95 [156] , CD40 [157] , DR5 [158] , and CFTR [159] , or signaling molecules such as NADPH-oxidase [160] , caspase 8 [161] , and Kv1.3 [162] , are concentrated and clustered within ceramide-enriched membrane domains, a process that is crucial for signal transduction via these molecules.
This change of membrane properties might be also the mechanism how ceramide acts on ion channel such as SOCs. Thus, it was shown that overexpression of the acid sphingomyelinase releasing ceramide from sphingomyelin or the addition of exogenous ceramide blocks the activity of SOCs. Moreover, receptors such as CD95 that release ceramide by activation of the acid sphingomyelinase also blocked SOCs via this pathway as evidenced in experiments using acid sphingomyelinasedeficient cells that failed to inhibit SOCs after CD95 ligation [152] . However, ceramide can be converted to sphingosine that also inhibits SOCs and triggers an increase of the membrane capacitance. Similar to CD95, the p75 Nerve growth factor receptor that activates the acid sphingomyelinase/ceramide also inhibited SOCs [151] . The cellular effectors of sphingosine and the mechanisms how this lipid acts are presently unknown. It might be possible that both lipids alter membrane biophysics that result in inhibition of SOCs.
Consistent with the trapping model of ceramide functions described above, ceramide was shown to also recruit TRPC6 channels to caveolae [153] . However, in contrast to the inhibition of store-operated calcium channels by ceramide, TRPC6 channels in endothelial cells were not inhibited by ceramide and Ca 2+ -influx even increased. This suggests that the membrane composition, in particular an increase of ceramide in membranes may have very different effects on different ion channels depending on the interaction of the particular ion channel with the membrane environment. Ceramide and sphingosine are very hydrophobic molecules and it seems highly unlikely that these lipids leave the membrane to directly interact with the acqueous pore of an ion channel. Ceramide has been shown to form small ceramide enrichedmembrane domains that spontaneously fuse to large ceramideenriched membrane platforms [156] . These domains and platforms were shown to trap receptor and signaling molecules [163] [164] [165] and it might be possible that these domains cluster Ca 2+ channels. These domains differ from other parts of the plasma membrane and it is very likely that the rigidity and the hydrophobicity of ceramide-enriched membrane domains is higher than that of other domains. Further, the transmembrane diameter might be altered in these domains compared to other parts of the membrane. The trapping of channels in such a domain may result in a conformational change of the protein to provide an energetically more stable status. This conformational change then may regulate the channels. Alternatively, it might be possible that ceramide-enriched membrane domains cluster signaling molecules that are integrated into the membrane via lipid anchors, for instance Src-like tyrosine kinase [166] . Clustering of such kinases may result in a transactivation of previously almost inactive kinases that then directly or indirectly phosphorylate intracellular residues in ion channels and thereby regulate these channels. This mechanisms was observed for Kv1.3 channels, although these studies employed short chain ceramides [166] and studies with physiologically more-relevant long chain ceramides are not available at present to our knowledge.
Sodium channels
The expression of voltage-gated Na+ channels (VGSCs), especially of Na v 1.5, Na v 1.6 and Na v 1.7 and of their splicing variants was found to be increased in many cancer types, including breast, prostate, lung (both small-cell, SCLC, and non-small-cell, NSCLC), cervical cancer, leukemia (for recent review see [167] ). In breast cancer, the neonatal isoform of Na v 1.5 (nNa v 1.5) would allow greater Na + entry into the cell, compared with the adult splice variant, with consequences of calcium homeostasis and of the regulation of intra-and extracellular pH [167] . In breast, prostate and NSCLC tumor cells, VGSC activity was shown to increase invasiveness by stimulating cysteine cathepsin activity [168] . Several independent preclinical studies demonstrated that pharmacological targeting of VGSC inhibits breast tumor growth and metastasis formation. α-Hydroxy-α-phenylamides, a new class of small molecules have potent inhibitory effect on voltage-gated sodium channels. Intraperitoneal injection of 10 mg/kg (every day for 24 days) of newly synthesized enantiomers of 3-chlorophenyl-α-hydroxyamide into mice bearing prostate cancer line PC3 xenografts resulted in a 60% decrease in tumor volume [169] . Importantly, the inhibitory effect on hERG was relatively small, up to 16% at the lowest dose used. In another study, administration of the VGSC inhibitor RS100642 (intravenously 0.25 mg/kg for 4 weeks) to mice developing 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer increased the survival of the animals by 50 days [170] . In a prostate cancer model using Mat-LyLu cells, injection of the general VGSC blocker tetrodotoxin at 200 nM concentration decreased metastasis and prolonged survival [171] . Tumor growth of orthotopic xenografts using the breast cancer line MDA-MB-231 expressing Na v 1.5 could be reduced by 30% applying 60 mg/kg (daily for four weeks) phenytoin, without affecting animal weight. Phenytoin reduced cancer cell proliferation in vivo and metastasis to the liver, lungs and spleen [172] . The important aspect of this study is that it identifies a drug that is already used at similar doses in the clinic to treat epilepsy which is also able to reduce breast cancer growth, although only partially. Another clinically used drug with metastasis-inhibitory effect of breast cancer cells is ranolazine: when injected into mice bearing MDA-MB-231 xenograft (50 mg/kg/day for 8 weeks), it significantly reduced lung colonization by these Na v 1.5-expressing human breast cancer cells [173] . Importantly, both the tumor volume, as assessed by bioluminescent imaging, and the number of lung metastasis were reduced to a similar extent to what has been obtained using the same cell line in which Na v 1.5 expression was abolished. Ranolazine is already used in the clinic as antianginal agent with antiarrhythmic properties [174, 175] .
Anionic channels
A strategy involving anion channels that was recently applied with success is targeting the ClC-3 channels, shown to be implicated in human glioma spread [176] . Chlorotoxin, (ChlTx) purified from the venom of the scorpion Leiurus quinquestriatus binds to matrix metalloproteinase-2 (MMP-2), a key factor involved in the process of tumor metastasis [177] and is also able to inhibit a voltage gated chloride channel that is specifically expressed on human astrocytoma and glioma cells [178] . This chloride channel was then identified as ClC-3, a type of Cl − /H + exchanger mainly expressed in endosomal/ lysosomal compartments (N95%). ChlTx has been reported to inhibit the migration and invasion of glioma cells [179, 180] . The facts that these ClC-3 channels are highly expressed in glioblastoma and ChlTx binds them as well as the observation that ChlTx preferentially binds to a variety of human malignancies, but shows little or no binding to normal human tissues that has allowed to exploit Chltx as a diagnostic agent or as a vehicle for drug delivery [181] . Indeed, a synthetic version of ChlTx, covalently linked to iodine 131 ( 131 I-TM-601) was used in Phase I clinical in patients with recurrent glioma [182] . TM601 has been also shown to reduce angiogenesis in vivo [183] . Furthermore, a liposome system containing doxorubicin and modified with chlorotoxin inhibited the growth of metastatic tumor by 85% and prevented the incidence of lung metastasis in mice bearing 4T1 tumors, displaying only low systemic toxicity [184] . ANO1/TMEM16A, initially identified from airway epithelial cells, is a member of Ca 2+ -activated Cl − channels (CaCCs) that function to regulate epithelial secretion and cell volume for maintenance of ion and tissue homeostasis. ANO1/TMEM16A has recently been shown to be highly expressed in several epithelium originated carcinomas, gastrointestinal stromal tumor, ESCC and pancreatic cancer. Knockdown of ANO1 breast cancer cell lines and other cancers inhibited proliferation, induced apoptosis, and reduced tumor growth in established cancer xenografts [185] [186] [187] . Compared with primary tumors, ANO1 expression decreases in metastatic lymph nodes of patients with squamous cell carcinoma of the head and neck. Stable reduction of ANO1 expression enhanced cell motility and increased metastases while decreasing tumor proliferation in an orthotopic mouse model [188] . The calciumactivated chloride channel inhibitor (CaCCinh)-A01, a low molecular weight inhibitor of ANO1 activity [189] and the recently identified ANO1 inhibitors idebenone (short-chain analog of CoQ10), miconazole and plumbagin [190] will hopefully be soon exploited for in vivo studies.
Conclusion and future direction
As illustrated in the above examples and in the summarizing Table 1 , this relatively new field has already importantly contributed to the identification of possible therapeutic agents for several different cancer types demonstrating the significant efficacy of ion-channel targeting drugs mostly in preclinical models. Now, knowing the set of the channels that contribute to the tumor development in a given tissue, a Table 1 Drugs targeting ion channels in vivo in cancer models. Please note that proof of specificity refers to evidence obtained by the lack of the observed pharmacological effect either in vitro or in vivo following knockdown of the ion channel expression. Therefore we do not considered as proof of specificity for this table the well-demonstrated specific effect of the different drugs/ molecules on channel proteins (e.g. the actions of TTX as well as that of anti-Kv10.1 antibodies are specific on the respective target proteins). For side-effects "n.d." stays for not determined, while "NO" refers to studies where the occurrence of side-effects was investigated at organ/tissue level or to the absence of apparent toxic effect. Please see for further details in the text. Ranolazine shRNA vs Nav1.5 Metastatic breast cancer; NO [173] combined therapy either using more than one channel inhibitors together or employing the drugs together with chemotherapeutics seems to be a possible future therapeutic approach. However, the main issue remains that in most cases the specificity of ion-channel targeting drugs for the observed anti-proliferative, pro-apoptotic, antiangiogenic or anti-metastatic effects has not been proven using genetic tools. While in several cases knock-down of the channel protein brings to a similar behavior of the cancer cells to that observed upon inhibition of the channels by pharmacological means, a clear-cut demonstration of possible pleiotropic effects should be performed by proving that a certain drug is not efficient anymore when the channel is not expressed. For example, the natural compound curcumin with potent antitumoral activity against various types of cancer (also in vivo), although widely considered as safe, is not selective, as it acts by multiple mechanisms. In fact, it inhibits K V 11.1 (hERG1) in human leukemic cell lines THP-1 [191] but also other channels, including Ora1 (I CRAC ) [192] . Therefore it would be mandatory to perform an in-depth study to understand whether its inhibitory effect of cancer growth is related to ion channel inhibition and if yes, to which one. Another main issue to be addressed in this field is the question of the possible side-effects. In many studied, this important point is not addresses at all. Independently of these issues, the reported studies point to the possibility of repositioning already approved drugs (for recent review see e.g. [193] ), such as ranolazine, clofazimine, astemizole, phenytoin, mibefradil, for which Phase II clinical trials for cancer studies can be directly undertaken. This is an important achievement, and hopefully future large-sale studies will clarify whether the use of these drugs in patients confer any protective effect on long-term scale for the respective tumors.
Finally, it would be desirable to exploit the novel techniques that might help drug delivery also for the modulators that target ion channels. Indeed, tumor-specific delivery of anticancer therapeutics could enhance the efficacy of anticancer drugs and could limit side effects associated with traditional chemotherapy. Various strategies including employment of pro-apoptotic peptides, oligonucleotides, liposomes, nanoparticles, radionuclides for delivery to the tumor site might be useful in this respect [194] [195] [196] . In addition, application of tumor-homing peptides is a very promising possibility, based also on numerous preclinical and clinical trials [194] . The so-far most successful strategy applies tumorpenetrating peptides like iRGD, iNGR and tLyp-1, which activate a transport pathway leading to the deep penetration of peptide/drug complex into the tumor tissue. These peptides have a consensus motif termed CendR which permits their binding to neurophilin-1 (NRP-1) receptors, shown to be over expressed in tumor tissues and to allow entrance of the drugs to endothelial cells (for recent review see [194] ). This strategy thus helps to overcome the limitation given by the fact that most of the drugs do not penetrate the tumor tissue effectively.
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